Literature DB >> 19801972

Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease.

Cristine Alves da Costa1, Claire Sunyach, Emilie Giaime, Andrew West, Olga Corti, Alexis Brice, Stephen Safe, Patrick M Abou-Sleiman, Nicholas W Wood, Hitoshi Takahashi, Mathew S Goldberg, Jie Shen, Frédéric Checler.   

Abstract

Mutations of the ubiquitin ligase parkin account for most autosomal recessive forms of juvenile Parkinson's disease (AR-JP). Several studies have suggested that parkin possesses DNA-binding and transcriptional activity. We report here that parkin is a p53 transcriptional repressor. First, parkin prevented 6-hydroxydopamine-induced caspase-3 activation in a p53-dependent manner. Concomitantly, parkin reduced p53 expression and activity, an effect abrogated by familial parkin mutations known to either abolish or preserve its ligase activity. ChIP experiments indicate that overexpressed and endogenous parkin interact physically with the p53 promoter and that pathogenic mutations abolish DNA binding to and promoter transactivation of p53. Parkin lowered p53 mRNA levels and repressed p53 promoter transactivation through its Ring1 domain. Conversely, parkin depletion enhanced p53 expression and mRNA levels in fibroblasts and mouse brains, and increased cellular p53 activity and promoter transactivation in cells. Finally, familial parkin missense and deletion mutations enhanced p53 expression in human brains affected by AR-JP. This study reveals a ubiquitin ligase-independent function of parkin in the control of transcription and a functional link between parkin and p53 that is altered by AR-JP mutations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801972      PMCID: PMC2952934          DOI: 10.1038/ncb1981

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  31 in total

1.  Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo.

Authors:  Jason E Coleman; Matthew J Huentelman; Sergey Kasparov; Beverly L Metcalfe; Julian F R Paton; Michael J Katovich; Susan L Semple-Rowland; Mohan K Raizada
Journal:  Physiol Genomics       Date:  2003-02-06       Impact factor: 3.107

2.  Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation.

Authors:  Roger P Leng; Yunping Lin; Weili Ma; Hong Wu; Benedicte Lemmers; Stephen Chung; John M Parant; Guillermina Lozano; Razqallah Hakem; Samuel Benchimol
Journal:  Cell       Date:  2003-03-21       Impact factor: 41.582

3.  Polyubiquitination of p53 by a ubiquitin ligase activity of p300.

Authors:  Steven R Grossman; Maria E Deato; Chrystelle Brignone; Ho Man Chan; Andrew L Kung; Hideaki Tagami; Yoshihiro Nakatani; David M Livingston
Journal:  Science       Date:  2003-04-11       Impact factor: 47.728

4.  Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease.

Authors:  K K Chung; Y Zhang; K L Lim; Y Tanaka; H Huang; J Gao; C A Ross; V L Dawson; T M Dawson
Journal:  Nat Med       Date:  2001-10       Impact factor: 53.440

5.  Wild-type but not Parkinson's disease-related ala-53 --> Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli.

Authors:  C A da Costa; K Ancolio; F Checler
Journal:  J Biol Chem       Date:  2000-08-04       Impact factor: 5.157

6.  Spatial distribution, cellular integration and stage development of Parkin protein in Xenopus brain.

Authors:  J M Horowitz; J Myers; V A Vernace; M K Stachowiak; G Torres
Journal:  Brain Res Dev Brain Res       Date:  2001-01-31

7.  RING finger 1 mutations in Parkin produce altered localization of the protein.

Authors:  Mark R Cookson; Paul J Lockhart; Chris McLendon; Casey O'Farrell; Michael Schlossmacher; Matthew J Farrer
Journal:  Hum Mol Genet       Date:  2003-09-30       Impact factor: 6.150

8.  Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress.

Authors:  Yakov Pesah; Tuan Pham; Heather Burgess; Brooke Middlebrooks; Patrik Verstreken; Yi Zhou; Mark Harding; Hugo Bellen; Graeme Mardon
Journal:  Development       Date:  2004-04-08       Impact factor: 6.868

9.  Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons.

Authors:  Matthew S Goldberg; Sheila M Fleming; James J Palacino; Carlos Cepeda; Hoa A Lam; Anushree Bhatnagar; Edward G Meloni; Nanping Wu; Larry C Ackerson; Gloria J Klapstein; Mahadevan Gajendiran; Bryan L Roth; Marie-Francoise Chesselet; Nigel T Maidment; Michael S Levine; Jie Shen
Journal:  J Biol Chem       Date:  2003-08-20       Impact factor: 5.157

10.  Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of a nuclear factor kappaB/CCAAT-binding transcription factor-1 complex.

Authors:  Chunhua Qin; Thu Nguyen; Jessica Stewart; Ismael Samudio; Robert Burghardt; Stephen Safe
Journal:  Mol Endocrinol       Date:  2002-08
View more
  88 in total

1.  Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect.

Authors:  Cen Zhang; Meihua Lin; Rui Wu; Xiaowen Wang; Bo Yang; Arnold J Levine; Wenwei Hu; Zhaohui Feng
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

Review 2.  Regulation of Parkin E3 ubiquitin ligase activity.

Authors:  Helen Walden; R Julio Martinez-Torres
Journal:  Cell Mol Life Sci       Date:  2012-04-19       Impact factor: 9.261

Review 3.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

Review 4.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

5.  PARK2 enhancement is able to compensate mitophagy alterations found in sporadic Alzheimer's disease.

Authors:  Patricia Martín-Maestro; Ricardo Gargini; George Perry; Jesús Avila; Vega García-Escudero
Journal:  Hum Mol Genet       Date:  2015-12-31       Impact factor: 6.150

6.  Impaired neurotransmitter release in Alzheimer's and Parkinson's diseases.

Authors:  Jie Shen
Journal:  Neurodegener Dis       Date:  2010-02-18       Impact factor: 2.977

7.  Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells.

Authors:  Houbo Jiang; Yong Ren; Eunice Y Yuen; Ping Zhong; Mahboobe Ghaedi; Zhixing Hu; Gissou Azabdaftari; Kazuhiro Nakaso; Zhen Yan; Jian Feng
Journal:  Nat Commun       Date:  2012-02-07       Impact factor: 14.919

Review 8.  Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications.

Authors:  Qian Huang; Maria E Figueiredo-Pereira
Journal:  Apoptosis       Date:  2010-11       Impact factor: 4.677

9.  Autophagy, apoptosis, and mitochondria: molecular integration and physiological relevance in skeletal muscle.

Authors:  Darin Bloemberg; Joe Quadrilatero
Journal:  Am J Physiol Cell Physiol       Date:  2019-04-24       Impact factor: 4.249

Review 10.  Programmed cell death in Parkinson's disease.

Authors:  Katerina Venderova; David S Park
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.